No Data
No Data
Express News | Galapagos NV-Granted Option to Exclusively License Uza-Cel for Global Development,Commercialization in Potential Future Solid Tumor Cancer Indications
Express News | Galapagos NV: Galapagos Has Been Granted an Option to Exclusively License Uza-Cel for Global Development and Commercialization in Head & Neck Cancer
Express News | Galapagos NV: Adaptimmune to Receive Additional Development and Sales Milestone Payments of up to a Maximum of $465 Mln
Express News | Galapagos NV: Adaptimmune to Receive Initial Payments of $100 Mln
Galapagos NV Unveils New Employee Incentive Plans
Galapagos NV Unveils Employee Subscription Plans
No Data